Pre-existing immunity against adenoviruses may compromise the efficacy of adenoviral vectors for vaccination and gene therapy. The purpose of this study was to determine whether encapsulation of adenovirus recombinants into biodegradable alginate microparticles could circumvent the vector-specific immune response. Mice were immunized either intranasally (i.n.) or intraperitoneally (i.p.) with human adenovirus type 5 (HAd5), resulting in the development of virus-specific antibodies. Immunized and naïve mice were inoculated with AdCA36lacZ (an E1-deleted HAd5 recombinant containing the bacterial b-galactosidase (LacZ) gene), encapsulated (E) into alginate microparticles, or nonencapsulated (NE) ie, as a virus suspension. LacZ expression in animals immunized once (1 Â ) or twice (2 Â ) with HAd5 and subsequently inoculated with NE-AdCA36lacZ (NE-Z) was significantly (Po0.001) reduced compared to those levels observed in NE-Z inoculated naïve mice, suggesting that the immune response against the vector adversely affected transgene expression. In contrast, there was only slight reduction (P40.05) in LacZ expression in mice immunized 1 Â or 2 Â with HAd5 that were subsequently inoculated with E-AdCA36lacZ (E-Z) compared to those levels obtained in E-Z inoculated naïve animals. Similar results were obtained with i.n. or i.p. inoculated animals. These results indicate that microencapsulation of recombinant adenovirus effectively circumvented the vector-specific immune response.
Introduction
Adenovirus-based vectors have considerable potential as delivery vehicles for both recombinant vaccines and somatic gene therapy. [1] [2] [3] However, a major disadvantage is the development of immunity to adenovirus. All human adenovirus (HAd) vectors (replication-competent, replication-defective, and helper-dependent) result in vector-specific immune responses that significantly reduce vector uptake following a second administration of the same vector. [4] [5] [6] The cellular immune response against the vector may kill the transduced cells expressing viral and transgene products, [7] [8] [9] [10] whereas the humoral response, especially neutralizing antibody, reduces virus uptake by the target cells on readministration of the same vector. [11] [12] [13] Moreover, pre-existing HAdneutralizing antibodies are common in the human population due to the ubiquitous nature of HAd serotypes, 14, 15 and therefore, may interfere with transgene expression even upon the first inoculation of the vector.
Immunosuppressive agents, such as cyclosporin, cyclophosphamide, 16 deoxyspergualin, 17 FK506, 18 and CTLA4Ig 19, 20 enhanced the duration of transgene survival. Another strategy to overcome vector-specific neutralizing immune responses is to switch the adenovirus serotype for vector construction. 5 Sequential administration of HAd, bovine adenovirus (BAd) and porcine adenovirus (PAd) could also circumvent vector-specific neutralizing immune response. 13 Masking of the capsid components of the virus by covalently linking polyethylene glycol (PEG) 21, 22 or N-(2-hydroxypropyl)methacrylamide (HPMA) 23 is another approach to curtail antibody-mediated virus neutralization. Retargeting of adenoviral vectors to specific cell receptors other than coxsackie/adenoviral receptor (CAR) will not only provide a mean to target-specific cells but also elude immunity to the vector. [24] [25] [26] [27] [28] Purified protein, DNA, bacteria, or viruses can be encapsulated in sodium alginate-based biodegradable microparticles, and can be delivered by various routes. [29] [30] [31] [32] [33] [34] Since the vector immunity is still considered a major hurdle in obtaining persistent transgene expression on repeated inoculations with HAd5 vectors, we attempted to extend the available options for combating the vectorspecific immune response to microencapsulation of HAd5 vectors. This paper demonstrates that encapsulation of an HAd5 recombinant into alginate microparticles could evade the vector-specific immune response.
Results

Development of HAd5-specific immune response in mice
In order to study the role of microencapsulation in eluding vector-specific immune response, mice were immunized either intranasally (i.n.) or intraperitoneally (i.p.) with HAd5 to develop HAd5-specific immune response. The purpose of selecting two routes of inoculation was to determine whether microencapsulation would be effective in circumventing both systemic as well as mucosal immunity to the vector. We also wanted to know whether the level of immune response affects the success of overcoming vector-specific immunity. Therefore, mice were inoculated once (1 Â ) or twice (2 Â ) with HAd5, serum samples were collected on days 21 and 35, respectively, and analyzed for the presence of HAd-specific IgG or IgA antibodies by ELISA.
The HAd5-specific IgG antibody titers were approximately 2.5 times higher in the 1 Â or 2 Â HAd5-immunized groups of the i.p. inoculated mice compared to those of i.n. inoculated animals (Figure 1a and b) . In contrast, the virus-specific IgA antibody titers were higher in the 1 Â or 2 Â HAd5-immunized groups inoculated i.n. compared to those of i.p. inoculated mice (Figure 2a and b) . The development of systemic IgA antibody titers was used as an indirect measure of mucosal immunity. HAd5-specific IgG or IgA antibody titers in naïve animals (PBS inoculated) were similar to the background levels (data not shown).
Since vector-specific neutralizing antibody response is mainly responsible for virus-neutralization before adsorption to the cells, the serum samples collected from mice immunized 1 Â or 2 Â with HAd5 were also analyzed for HAd5-specific neutralizing antibody by virus-neutralization assay. In 1 Â HAd5-immunized groups, the virus neutralizing antibody titers were 400 and 800 in i.n. or i.p. inoculated mice, respectively (Table  1) , and were 800 and 1600 in i.n. or i.p. 2 Â HAd5-immunized groups, respectively (Table 1) . Virus-neutralizing antibody titers in naïve animals (PBS-inoculated) were close to the background levels.
Levels of LacZ expression by AdCA36lacZ in mice having pre-existing adenovirus-specific immune response
We previously demonstrated that in mice inoculated i.n. or i.p. with nonencapsulated-AdCA36lacZ (NE-Z), the maximum LacZ expression in various tissues was observed on day 1 post-inoculation. 13 In a preliminary study, the highest level of LacZ expression in different tissues of mice inoculated i.n. or i.p. with encapsulatedAdCA36lacZ (E-Z) was observed on day 3 post-inoculation (data not shown). Therefore, mice inoculated with NE-Z or E-Z were sacrificed on day 1 or 3 postinoculation, respectively.
To address the issue of circumvention of pre-existing immunity to the vector by microencapsulation, naïve, 1 Â HAd5-immunized or 2 Â HAd5-immunized mice were inoculated with NE-Z or E-Z. The trachea and lungs were collected from i.n. inoculated mice, whereas the spleen, liver, peritoneal cells, kidneys and mesenteric lymph nodes were collected from i.p. inoculated mice to monitor LacZ expression by LacZ assay. The same route of inoculation was used to inoculate mice with NE-Z or E-Z that was initially used for inoculating with PBS (naïve) or HAd5.
Animal inoculated with i.n. route
In naïve mice inoculated i.n. with NE-Z (Naïve/NE-Z/ i.n.), expression of LacZ in the trachea and lungs was approximately 38 and 43 ng/g tissue, respectively (Figure 3a and b) . However, in mice 1 Â immunized with HAd5 and then inoculated i.n. with NE-Z (HAd5/NE-Z/i.n.), expression of LacZ in the trachea and lungs were reduced to approximately 33% and 36%, Figure 1 HAd5-specific IgG ELISA antibodies in mice inoculated with HAd5. Six-to-eight week-old BALB/c mice (5 animals/group) were immunized (a) i.n.) or (b) i.p. either with PBS or once (1 Â )/twice (2 Â ) with 1 Â 10 8 p.f.u. of HAd5. There was no difference between NE-Z and E-Z groups at this stage. Serum samples were collected on 3 and 5 weeks post-inoculation and analyzed to determine the levels of virus-specific IgG antibodies by ELISA. Each point represents the geometric mean value for five animals. NE-Z, nonencapsulated AdCA36lacZ; E-Z, AdCA36lacZ encapsulated into alginate microparticles.
Circumvention of vector-specific immune response Sailaja et al respectively, of those levels obtained in the Naïve/ NE-Z/i.n. group. The expression of LacZ was reduced to approximately 16% and 15% in the trachea and lungs, respectively, in HAd5-HAd5/NE-Z/i.n. compared to the Naïve/NE-Z/i.n. animals suggesting that there is significant (Po0.001) inhibition of transgene expression in the presence of immune response to the vector.
In naïve mice inoculated i.n. with E-Z (Naïve/E-Z/ i.n.), expression of LacZ in the trachea and lungs was approximately 20 and 25 ng/g tissue, respectively (Figure 3a and b). In mice 1 Â immunized with HAd5 and inoculated i.n. with E-Z (HAd5/E-Z/i.n.), the expression of LacZ in the trachea and lungs was approximately 86% and 90%, respectively, of those levels obtained in the Naïve/E-Z/i.n. group. The expression of LacZ was only reduced to 75% and 80% in the trachea and lungs, respectively, in HAd5-HAd5/E-Z/i.n. compared to the Naïve/E-Z/i.n. mice. These results indicate that high levels of transgene expression were observed and were not significantly (P40.05) inhibited even in the presence of HAd5-specific neutralizing antibody response.
Animal inoculated with i.p. route
In naïve mice that were inoculated i.p. with NE-Z (Naïve/NE-Z/i.p.), transgene expression was approximately 57, 45, 19, 9.5 and 7 ng/g tissue in the spleen, liver, peritoneal cells, kidneys and mesenteric lymph nodes, respectively (Figure 4a-e), whereas in mice 1 Â -immunized with HAd5 when inoculated i.p. with NE-Z (HAd5/NE-Z/i.p.), LacZ expression in the spleen, liver, peritoneal cells, kidneys and mesenteric lymph nodes were reduced to approximately 22%, 28%, 27%, 30% and 23%, respectively, of the levels obtained in the Naïve/ NE-Z/i.p. mice. Transgene expression was reduced to 13%, 14%, 5%, 8% and 7% in the spleen, liver, peritoneal cells, kidneys and mesenteric lymph nodes, respectively, in HAd5-HAd5/NE-Z/i.p compared to those levels observed in Naïve/NE-Z/i.p. animals. These results further confirm that immunity to vector has a significant (Po0.001) adverse affect on transgene expression by an adenoviral vector.
On the other hand, in naïve animals inoculated i.p. with E-Z (Naïve/E-Z/i.p.), expression of LacZ was approximately 28, 22, 12, 5 and 3.5 ng/g tissue in the spleen, liver, peritoneal cells, kidneys and mesenteric lymph nodes, respectively (Figure 4a-e) . In HAd5/E-Z/ i.p. mice, LacZ expression in the spleen, liver, peritoneal cells, kidneys and mesenteric lymph nodes were only reduced to approximately 90%, 92%, 83%, 82% and 80%, respectively, of those levels obtained with Naïve/ E-Z/i.p. Furthermore, in HAd5-HAd5/E-Z/i.p. animals, transgene expression in the spleen, liver, peritoneal cells, Figure 2 HAd5-specific IgA ELISA antibodies in mice inoculated with HAd5. Six-to-eight-week-old BALB/c mice (5 animals/group) were immunized (a) i.n. or (b) i.p. either with PBS or once (1 Â )/twice (2 Â ) with 1 Â 10 8 p.f.u. of HAd5. There was no difference between NE-Z and E-Z groups at this stage. Serum samples were collected on 3 and 5 weeks post-inoculation and analyzed to determine the levels of virus-specific IgA antibodies by ELISA. Each point represents the geometric mean value for five animals. NE-Z, nonencapsulated AdCA36lacZ; E-Z, AdCA36lacZ encapsulated into alginate microparticles. 
Discussion
Induction of an immune response to the vector significantly inhibits the levels and duration of transgene expression. Some of the approaches to elude immunity to HAd vectors include immunosuppression, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] retargeting HAd vectors after masking the binding site for CAR, 25, 26 alteration of the immunodominant capsid epitopes, 39 use of different HAd serotypes [40] [41] [42] and use of human and nonhuman adenovirus vectors in sequential administration. 13 However, it has been suggested that repeated intramuscular (i.m.) inoculation with helperdependent HAd vectors could be done even in the presence of pre-existing immunity. 43 The focus of this study was to develop a simple method to evade preexisting immunity so that repeated inoculations with the same vector (replication-competent, replication-defective, conditional replication-competent or helper-dependent) provide the required levels of transgene expression at each inoculation. We used biodegradable alginate microparticles to encapsulate an HAd5 recombinant (AdCA36lacZ) in an attempt to overcome HAd5-specific immune response.
In order to mimic the conditions of pre-existing immunity to the vector, mice were first immunized with HAd5 to test the hypothesis that microencapsulation of HAd5 vector could escape the vector-specific immune response. We tested the effect of levels and types (systemic or mucosal) of immunity to HAd5 on transgene expression from the vector on subsequent inoculation. In HAd5-immunized mice, LacZ expression by NE-Z, ie AdCA36lacZ as a virus suspension, was significantly (Po0.001) inhibited compared to expression in naïve animals and its level was dependent on the level of vector-specific immune response. This concept has been demonstrated previously. 13, 44 However, in HAd5-immunized mice, transgene expression following inoculation with E-Z, ie AdCA36lacZ encapsulated into alginate microspheres, was slightly reduced (10% in 1 Â HAd5-immunized, and 20-25% in 2 Â HAd5-immunized) compared to levels obtained in naïve animals. Similar results were obtained with i.n. and i.p. routes of inoculation indicating that microencap-sulation could effectively elude both systemic and mucosal immunity to the vector. Use of polyethylene glycol and cationic lipid to coat HAd vectors 45 and poly(lactic-glycolic) acid (PLGA) copolymer encapsulation 46 have been also shown to elude virus-neutralizing antibodies.
It was not surprising to observe that in naïve animals LacZ expression with E-Z was approximately 50% of the levels obtained with NE-Z inoculated mice. It has been shown that the maximum levels of LacZ expression in mice inoculated with NE-Z was on day 1 and declined rapidly thereafter, 13 whereas, transgene expression in animals inoculated with E-Z peaked at day 3 and then declined slowly (data not shown). Therefore, transgene expression with two types of preparations (NE-Z and E-Z) that reach the maximum levels at different times postinoculation (day 1 for NE-Z and day 3 for E-Z) should be compared with caution. It is interesting to note that in HAd5-immunized mice there was at least 10-25% decline in LacZ expression on inoculation with E-Z. This decline may be due to (1) a limited accessibility of the virus onto or into the microspheres to the virus-neutralizing antibody, (2) a small percentage of microspheres may be degraded in the intracellular spaces releasing HAd5 recombinant that could be neutralized by the vector-specific antibody, (3) The cell-mediated immune response against the viral antigens may be responsible in removing cells that are also expressing the transgene. 
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More than 70% of the microspheres described in this study were approximately 5-10 mm in size, and therefore, it is expected that the majority of them will be taken up by macrophages and dendritic cells. 47 It appears that alginate microspheres may be an attractive delivery system to target macrophages and dendritic cells. However, it has been suggested that preferential activation of macrophages and dendritic cells by adenovirus leads to acute inflammatory response in mice. 48 There is a need to study the role of alginate microparticles in modulating immune response through macrophages and dendritic cells. It is believed that adenovirus will be released from microparticles slowly over a period, thereby reducing the toxicity mediated by the activation of macrophages and dendritic cells by adenovirus. It will be important to study the safety aspects of microencapsulated adenovirus in mice to verify our hypothesis. Development of microspheres having a size range Figure 4 Circumvention of adenovirus-specific immune response by microencapsulation of AdCA36lacZ. Six-to-eight-week-old BALB/c mice (5 animals/ group) were immunized i.p. with PBS or once (1 Â )/twice (2 Â ) with 1 Â 10 8 p.f.u. of HAd5, and following development of HAd5-specific antibodies animals were inoculated i.p. with a nonencapsulated (NE-Z) or encapsulated (E-Z) in alginate microspheres preparation containing 2.5 Â 10 8 p.f.u. of AdCA36lacZ. (a) The spleen, (b) liver, (c) peritoneal cells, (d) kidneys, and (e) mesenteric lymph nodes were collected and analyzed for LacZ expression. Each point represents the mean value for five animals 7 SD. *, indicates that data were statistically significant (P40.05).
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Sailaja et al of 0.5-2 mm that could be taken up by a number of other cell types would increase the versatility of this delivery system. Furthermore, targeted delivery of microspheres to specific cells is another attractive possibility. Microparticles containing either adenovirus, DNA or both could be delivered by various routes (oral, i.n., s.c., i.m. or i.p.) without any obvious side-effects. 34 We are working on the hypothesis that alginate microparticles are taken up by the cells via endocytosis and virus release from microparticles is mainly due to acidic pH and/or enzymatic digestion.
Materials and methods
Cell lines and viruses
Human cell lines, HeLa and 293, were grown as monolayer cultures in Eagle's minimum essential medium (MEM) (Life Technologies, Gaithersburg, MD, USA) supplemented with 5% or 10% reconstituted fetal bovine serum (FetalClone III; Hyclone, Logan, UT, USA), respectively, and 50 mg/ml gentamicin. HAd5 was grown on HeLa cells and AdCA36LacZ recombinant, 49 a replication-defective HAd5 recombinant containing the bacterial b-galactosidase (LacZ) gene in the E1 region under the control of mouse cytomegalo virus promoter (a kind gift from Dr Frank Graham, Departments of Biology and Pathology, McMaster University, Hamilton, Ontario, Canada) was grown in 293 cells. The virus purification by cesium chloride-density gradient centrifugation was done as previously described. 50 Viruses were titrated in 293 cells by plaque assay.
Microencapsulation of HAd5 recombinant
A purified preparation of AdCA36LacZ recombinant was encapsulated into sodium alginate microspheres as described previously. 34 One milliliter suspension of microspheres was expected to contain a maximum of 5 Â 10 9 p.f.u. of AdCA36LacZ. The size of microspheres was measured by Microtrak Particle Analyzer and the majority of them were 5-10 mm in diameter.
Experimental design
Eight-to-ten-weeks old female BALB/c mice were purchased from Harlan Sprague-Dawley, Indianapolis, IN, USA. Animals were fed and watered normally until the end of the experiment. Mice were randomly grouped into 12 groups (5 animals/group). Six groups were inoculated i.n. and the remaining groups were inoculated i.p.
The experimental design is presented in Table 2 . For i.n. inoculation, animals were anesthetized with sodium pentobarbital. On day 0, two naïve groups were inoculated with 50 ml of PBS and four groups were inoculated with a purified preparation containing 1 Â 10 8 p.f.u. of HAd5. Subsequently, on day 21, one naïve and one HAd5-immunized groups were inoculated i.n. with 2.5 Â 10 8 p.f.u. of NE AdCA36lacZ (for simplicity, the term ''Z'' is used for this recombinant), and the other naïve and HAd5 groups were inoculated i.n. with 2.5 Â 10 8 p.f.u. of AdCA36lacZ E into alginate microspheres. The remaining two HAd5-immunized groups were inoculated a second time with 1 Â 10 8 p.f.u. of HAd5 on day 21. On day 35, one group immunized twice with HAd5 was inoculated i.n. with 2.5 Â 10 8 p.f.u. of NE-Z and the other group was inoculated i.n. with 2.5 Â 10 8 p.f.u. of E-Z (AdCA36lacZ encapsulated into alginate microspheres). The lungs and trachea were collected on day 1 or 3 following NE-Z or E-Z inoculation, respectively. Blood samples were collected on days 21 and/or 35.
For i.p. inoculation, two naïve groups were inoculated with 100 ml of PBS, and four groups were inoculated with a purified preparation containing 1 Â 10 8 p.f.u. of HAd5 on day 0. Subsequently, on day 21, one naïve and one HAd5-immunized group were inoculated i.p. with The serum samples were used to examine the development of virus-specific antibodies by enzymelinked immunosorbent assay (ELISA) and virus neutralization assay. The tissue samples were processed to measure the expression of LacZ by b-galactosidase assay.
ELISA
The serum samples obtained from mice were used to detect HAd5-specific IgG and IgA antibodies by ELISA as previously described. 51 Briefly, 96-well ELISA plates were coated with a purified preparation of HAd5 (10 mg/ ml) and then reacted with serial dilutions of each of the test sample. For secondary antibody, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Bio-Rad, Hercules, CA, USA) or IgA (Southern Biotechnology Associates, Birmingham, AL, USA) was used to detect IgG or IgA antibody, respectively. The OD was measured at dual wavelength of 490-650 nm using an ELISA reader (Molecular Devices, Sunnyvale, CA, USA). The reciprocal of the highest serum dilution with an OD reading of at least the mean 7 2SD above negative control sera was taken as the ELISA antibody titer. The data represent the geometric means from five animals. Since the serum samples were serially diluted, the geometric mean is usually a preferred way to analyze ELISA antibody titer. However, SD were within normal limits when ELISA antibody titer were analyzed by the arithmetic mean (data not shown).
Virus neutralization assay
Serum samples from mice were tested for the presence of HAd5-neutralizing antibodies as described previously. 13 Briefly, serial dilutions of each of the serum sample were reacted with 100 p.f.u. of HAd5 for 1 h at 371C. The numbers of viable HAd5 remaining after the antibody treatment were identified by plaque assay on 293 cells. The virus neutralization antibody titer was the reciprocal of the highest serum dilution that leads to reduction of number of virus plaque by at least 50%.
b-Galactosidase assay b-Galactosidase assay was performed as previously described. 33 The intensity of colorimetric reaction was measured spectrophotometrically at 420 nm. LacZ activity is expressed as nanograms per gram of tissue using purified b-galactosidase as a control.
Statistical analysis
Statistical analysis of the data collected from the animal inoculation study was done using Student's t-distribution. Significance was set at Po0.05.
